First-line drugs for hypertension
Open Access
- 8 July 2009
- journal article
- research article
- Published by Wiley in Cochrane Database of Systematic Reviews
- No. 3,p. CD001841
- https://doi.org/10.1002/14651858.cd001841.pub2
Abstract
Sustained elevated blood pressure, unresponsive to lifestyle measures, leads to a critically important clinical question: What class of drug to use first-line? This review answers that question. To quantify the benefits and harms of the major first-line anti-hypertensive drug classes: thiazides, beta-blockers, calcium channel blockers, angiotensin converting enzyme (ACE) inhibitors, alpha-blockers, and angiotensin II receptor blockers (ARB). Electronic search of MEDLINE (Jan. 1966-June 2008), EMBASE, CINAHL, the Cochrane clinical trial register, using standard search strategy of the hypertension review group with additional terms. Randomized trials of at least one year duration comparing one of 6 major drug classes with a placebo or no treatment. More than 70% of people must have BP >140/90 mmHg at baseline. The outcomes assessed were mortality, stroke, coronary heart disease (CHD), cardiovascular events (CVS), decrease in systolic and diastolic blood pressure, and withdrawals due to adverse drug effects. Risk ratio (RR) and a fixed effects model were used to combine outcomes across trials. Of 57 trials identified, 24 trials with 28 arms, including 58,040 patients met the inclusion criteria. Thiazides (19 RCTs) reduced mortality (RR 0.89, 95% CI 0.83, 0.96), stroke (RR 0.63, 95% CI 0.57, 0.71), CHD (RR 0.84, 95% CI 0.75, 0.95) and CVS (RR 0.70, 95% CI 0.66, 0.76). Low-dose thiazides (8 RCTs) reduced CHD (RR 0.72, 95% CI 0.61, 0.84), but high-dose thiazides (11 RCTs) did not (RR 1.01, 95% CI 0.85, 1.20). Beta-blockers (5 RCTs) reduced stroke (RR 0.83, 95% CI 0.72, 0.97) and CVS (RR 0.89, 95% CI 0.81, 0.98) but not CHD (RR 0.90, 95% CI 0.78, 1.03) or mortality (RR 0.96, 95% CI 0.86, 1.07). ACE inhibitors (3 RCTs) reduced mortality (RR 0.83, 95% CI 0.72-0.95), stroke (RR 0.65, 95% CI 0.52-0.82), CHD (RR 0.81, 95% CI 0.70-0.94) and CVS (RR 0.76, 95% CI 0.67-0.85). Calcium-channel blocker (1 RCT) reduced stroke (RR 0.58, 95% CI 0.41, 0.84) and CVS (RR 0.71, 95% CI 0.57, 0.87) but not CHD (RR 0.77 95% CI 0.55, 1.09) or mortality (RR 0.86 95% CI 0.68, 1.09). No RCTs were found for ARBs or alpha-blockers. First-line low-dose thiazides reduce all morbidity and mortality outcomes. First-line ACE inhibitors and calcium channel blockers may be similarly effective but the evidence is less robust. First-line high-dose thiazides and first-line beta-blockers are inferior to first-line low-dose thiazides.Keywords
This publication has 141 references indexed in Scilit:
- The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertensionThe American Journal of Cardiology, 1994
- Adverse treatment effects in the trial of the European Working Party on High Blood Pressure in the ElderlyAmerican Journal Of Medicine, 1991
- Body mass index and prognosis in elderly hypertensive patients: A report from the European Working Party on High Blood Pressure in the ElderlyAmerican Journal Of Medicine, 1991
- Comparison of the Antihypertensive Efficacy and Adverse Reactions to Two Doses of Bendrofluazide and Hydrochlorothiazide and the Effect of Potassium Supplementation on the Hypotensive Action of Bendrofluazide: Substudies of the Medical Research Council's Trials of Treatment of Mild Hypertension: Medical Research Council Working PartyThe Journal of Clinical Pharmacology, 1987
- Low‐dose Antihypertensive Treatment with a Thiazide Diuretic Is Not DiabetogenicActa Medica Scandinavica, 1986
- Systolic Hypertension in the Elderly Program (SHEP): Antihypertensive efficacy of chlorthalidoneThe American Journal of Cardiology, 1985
- The Oslo study: CHD risk factors, socioeconomic influences, and interventionAmerican Heart Journal, 1983
- The Effect of Treatment on Mortality in Mild HypertensionNew England Journal of Medicine, 1982
- BETA-BLOCKERS OR DIURETICS IN HYPERTENSION? A SIX YEAR FOLLOW-UP OF BLOOD PRESSURE AND METABOLIC SIDE EFFECTSThe Lancet, 1981
- Effects of treatment in hypertension results of a controlled studyJournal of Chronic Diseases, 1966